QTTB
QTTB
NASDAQ · Biotechnology

Q32 Bio Inc

$9.23
+0.46 (+5.25%)
As of Sep 28, 10:29 PM ET ·
Financial Highlights (FY 2026)
Revenue
130.20M
Net Income
72.25M
Gross Margin
—
Profit Margin
55.5%
Rev Growth
+155.8%
D/E Ratio
2.29
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 64.5% 64.5% 64.5%
Operating Margin 28.5% -28.5% -30.0% -31.9%
Profit Margin 55.5% -27.8% -31.6% -27.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 130.20M 8.10M 7.51M 6.99M
Gross Profit — 5.23M 4.85M 4.51M
Operating Income 37.08M -2,307,109 -2,257,916 -2,232,357
Net Income 72.25M -2,253,266 -2,377,750 -1,909,981
Gross Margin — 64.5% 64.5% 64.5%
Operating Margin 28.5% -28.5% -30.0% -31.9%
Profit Margin 55.5% -27.8% -31.6% -27.3%
Rev Growth +155.8% +18.0% -0.1% +13.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 91.05M 26.39M 25.22M 27.43M
Total Equity 39.78M 33.72M 33.32M 32.74M
D/E Ratio 2.29 0.78 0.76 0.84
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 38.02M -3,375,106 -3,186,219 -2,905,098
Free Cash Flow — -1,035,116 -1,228,536 -1,335,718